Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 3/20 | 0.43 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 4/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106570 | 1.00 | CFTR (0.43) | CFTRCETPMEN1POLBKMT2A | |
| SCHEMBL5107338 | 0.94 | CETP (0.46) | CFTRCETPMEN1POLBKMT2A | |
| SCHEMBL5107542 | 0.94 | CETP (0.46) | CFTRCETPMEN1POLBKMT2A | |
| SCHEMBL5113222 | 0.85 | CFTR (0.43) | CFTRCETP | |
| SCHEMBL5107522 | 0.85 | CFTR (0.44) | CFTRMEN1POLBKMT2ALMNA | |
| SCHEMBL14192036 | 0.85 | CFTR (0.44) | CFTRMEN1POLBKMT2ALMNA | |
| SCHEMBL5104284 | 0.80 | LMNA (0.41) | CFTRMEN1POLBKMT2ALMNA | |
| SCHEMBL14192033 | 0.80 | LMNA (0.41) | CFTRMEN1POLBKMT2ALMNA | |
| SCHEMBL4322706 | 0.80 | CETP (0.37) | CETPMEN1POLBKMT2ADGAT2 | |
| SCHEMBL13892428 | 0.80 | CETP (0.37) | CETPMEN1POLBKMT2ADGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080124402-A1 | N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators | MERCK & CO., INC. (US) | 2008-05-29 | — | — | US | claimed |
| EP-1807076-A1 | N-(PYRIDIN-3-YL)-2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2007-07-18 | — | — | EP | claimed |
| WO-2006060108-A1 | N-(PYRIDIN-3-YL)-2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2006-06-08 | — | — | WO | claimed |
| US-20230122310-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2023-04-20 | — | — | US | disclosed |
| WO-2022204184-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| US-20210214316-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2021-07-15 | — | — | US | disclosed |
| WO-2021097046-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20200360523-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-11-19 | — | — | US | disclosed |
| US-20080124402-A1 | N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators | MERCK & CO., INC. (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080124402-A1 | N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators | MERCK & CO., INC. (US) | 2008-05-29 | — | — | US | disclosed |
| EP-1807076-A1 | N-(PYRIDIN-3-YL)-2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006060108-A1 | N-(PYRIDIN-3-YL)-2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214316-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | CFTR 3585/4885CETP 1337/4885MEN1 2250/4885 |
| US-20080124402-A1 | N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators | SHBG, AR, NR5A1 | CFTR 4732/4885CETP 3546/4885MEN1 2668/4885 |
| US-20200360523-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | CFTR 3585/4885CETP 1337/4885MEN1 2250/4885 |
| US-20230122310-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | CFTR 3585/4885CETP 1337/4885MEN1 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.